NeuroQore, Inc., is set to commercialize a new patented monophasic repetitive transcranial magnetic stimulation (rTMS) system with a potentially improved remission rate. The first unit of the NeuroQore rTMS system was installed at the Royal Ottawa Mental Health Centre in July 2015 and successfully passed tolerability testing on healthy volunteers in a pilot project. The company is now in the midst of recruiting patients for the next round of testing. Preliminary clinical data is promising and has prompted installation of more units to recruit more patients faster.